Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Zacks highlights Catalyst Pharmaceuticals (CPRX) as a compelling value stock, citing its #2 (Buy) Zacks Rank and 'A' ratings for both Value and VGM Style Scores. The company's forward P/E ratio is an attractive 11.12, and the consensus earnings estimate for fiscal year 2025 has increased by $0.10 to $2.25 per share following upward revisions by four analysts in the last 60 days; CPRX also has a 28.2% average earnings surprise.

Analysis

Catalyst Pharmaceuticals (CPRX) is highlighted by Zacks Investment Research as a strong candidate for value-focused investors, carrying a #2 (Buy) Zacks Rank and an 'A' grade for its VGM (Value, Growth, Momentum) Score. The company, a commercial-stage biopharmaceutical firm focused on rare diseases, also receives an 'A' for its Value Style Score, supported by a forward Price-to-Earnings (P/E) ratio of 11.12. This valuation is further reinforced by positive analyst activity; for fiscal year 2025, four analysts have revised their earnings estimates upward in the last 60 days. Consequently, the Zacks Consensus Estimate for earnings per share has risen by $0.10 to $2.25. Catalyst Pharmaceuticals also demonstrates a track record of exceeding expectations, with an average earnings surprise of 28.2%. According to Zacks' methodology, stocks with a #1 or #2 Rank combined with Style Scores of 'A' or 'B', such as CPRX, are considered to have a higher likelihood of outperforming the market in the near term, particularly due to positive earnings estimate revisions.

Key Decisions for Investors

• Investors may consider Catalyst Pharmaceuticals (CPRX) as a potential value investment, given its #2 (Buy) Zacks Rank, 'A' Value Score, and a forward P/E of 11.12, suggesting it may be undervalued relative to its earnings potential.
• The upward trend in earnings estimates for fiscal 2025, with four analysts revising estimates upwards and the consensus EPS increasing to $2.25, alongside a historical average earnings surprise of 28.2%, indicates positive momentum that warrants monitoring.
• Given the combination of a strong Zacks Rank and high Style Scores, CPRX could be considered for portfolios aiming for near-term outperformance, particularly if aligning with a value-oriented investment strategy.